Aller au contenu principal
Fermer

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
information fournie par Boursorama CP 09/11/2020 à 17:45

­ - Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5%
­ - Presence of liver metastases had a notable impact on outcomes: in patients without liver metastases, an ORR of 34.8% and a median progression-free survival (PFS) of 5.6 months were achieved
­ - Treatment associated with changes in the tumor microenvironment characterized by a significant and sustainable immune response and activity against the tumor

Conference call to take place on November 12, at 6:00 p.m. CET (in English).

.../...

Valeurs associées

0,8350 EUR Euronext Paris +0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.

91,99 -1,41%
8 183,34 -0,07%
75,18 -0,32%
Or
4 542,47 0,00%
1,166 0,00%
Chargement...